Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Watch out for a flood of news releases.
Final post.
adieu
Sapere, you can be proud you know about AMBS. You can ask the first 1 million on the Italian streets and they would not have heard of AMBS. You are in good shape.
Arrivederci!
There was no insight. Science speaks for itself. It does not matter what I or anyone else "believes". I believe in ghosts by the way.
Worry not, even if it goes to $0.0001. Just add more. PPS will not be here for long. It will be $10+ in 12 months. Wait for the data to be announced.
I am moving on. Last day. Good luck lads.
Bashing and Shorting a company and its stock is fine by me, if there is a logical reasoning behind it. If a company's management is working against the interests of its shareholders, if the pipeline is stagnant, if the policies are counter-productive and lack vision, if insiders are involved in litigations, then yes, I do bash a company, and you should too.
When a company like AMBS is doing everything right for the shareholders, has a breakthrough pipeline that can improve the lives of billions of patients who have no hope right now and are dying a slow death every minute of their lives, then to sabotage such good work by bashing and shorting is unethical.
There are hundreds of companies that deserve a bit of stick, by all means go and bash them. But do it for the right reason.
Imagine yourself being a young intern trying to make a career and have a decent life. If you find there is someone who is always sabotaging your good work, how would you feel. Think.
Or think about the medicines you take when you are sick, or the vaccine injections you were given when you were a baby. Had these not made it to the clinics (due to investors sabotaging the good work and research when these were in clinical trials), you would be dead by now, even worse, you could be living with polio, TB for all your life. Life is a gift, appreciate it.
It is my earnest request to all investors, for the sake of the suffering patients (it includes you, your family, your friends) who are waiting for that moment in their lives where they could walk, play and just live like you do, to do the right thing.
After all that AMBS has accomplished since Nov 2012, the stock should have broken the $1 barrier by now. AMBS deserves better. Give AMBS and the patients, a chance. It will make you a lot more money, if money is all you care for. I want money too, but not by inflicting suffering to patients and snatching hope away.
I am sure you don't want to be the person who looks in the eyes of a Parkinson's patient and tells him/her "Mate, you will never get to live a normal life, because I am sabotaging the cutting-edge research that is being done for you".
By bashing and shorting, you may have won and/or continue winning a lot of money, but from where I am standing, I see that you are losing. From where I am standing, I see you losing the chance to help someone, including your family and perhaps yourself, who needs help immediately. Your loved ones and the generations to come will remember you as a modern day Ahriman from the Persian mythology.
From where I am standing, you have already lost.
My apologies sir, I did not check with you before posting.
Many have asked why I say $10-25 is possible in 1 year. All I can respectfully say is do you own research and set your own goals.
Genzyme was acquired by Sanofi in 2011 for $20.1B. FerroKin Biosciences, with a staff of 7 employees, was acquired by Shire. In 2011, Alexion Pharmaceuticals reported $783M in revenue based on sales of its only product Soliris, a drug that treats a population of just 10,000 patients.
Ophthalmology has taken on significantly greater interest from major players in the biopharmaceutical industry: Pfizer, Allergan, Alcon, Novartis, Merck and Roche cover 70% of the $10 billion market. These companies have added drug candidates to their pipelines through strategic transactions.
When you have breakthrough biology, then the pps, the financials, the technical indicators, the market perception, the analysts' opinions, all get tossed out of the window.
All the hard and dirty work was done over the past 10 months. Watch out for a major partnership, that will dwarf BD. The rise of AMBS will be swift and clean.
I understand your point. It sounds baseless because most investors have access to only the information that the company or analysts put out. Those with access to all medical journals and the latest peer-reviewed papers (more than 1000 articles are published every day) or atleast with a scientific research background, have more detailed information and understand the scientific implications of a discovery.
Valuing a company for what it has, is a 1+2=3 step. Given 1 and 2, everyone (almost !) can answer 3. My valuation is based on things that are not yet public. Stay tuned. The second orphan indication (and what it brings to the table) is outrageous.
JN is hoping to release his updated article on AMBS after 2nd Orphan indication is made public. He is of the opinion that this will change everything.
BD will be performing the 60 patient clinical trial as well as the CLIA work. As I mentioned in my earlier posts, CED partnership has been finalized, and will be announced in the next 14 days.
Keep in mind that if MANF toxicology results are favorable (that is, none to minimal side effects), it would greatly reduce the time spent on assessing the side effects for various MANF indications.
For his age (very young) and experience (hardly), Gerald is very well informed of the field and takes his job seriously. The pipeline is beyond belief. This is not how start-ups are "supposed" to be. This is the stuff worthy of leading big pharma of the world. No wonder Merk, Novartis, Bayer, Amgen former officers believe in Dr. John Commissiong's discovery.
Do not forget that AMBS is NOT a typical start-up with 1 drug in the pipeline, which if fails, spells doom for the company and wipes out the shareholders.
Remember what Gerald said: Usually you are searching for positive data. With us it is the other way around. We have so much positive data, we are trying to re-prioritize to commercialize as soon as possible.
Amarantus Bioscience Holdings Announces Private Placement of Convertible Debentures and Warrants
Sept 4, 2013
1. AMBS may force the institutional investors to convert their entire note, and call for the forced exercise of the warrant, in the event AMBS shares trade at or above $0.10/share for a period of 20 consecutive trading days.
2. The institutional investors agreed to 'no shorting' for a period of 12 months.
3. "This financing transaction allows the Company to execute on its business plan of advancing LymPro into commercialization, while also giving us the opportunity to complete the MANF pipeline re-prioritization toward orphan indications and improve the Company's patent portfolio," said Gerald E. Commissiong, President & CEO of Amarantus.
4. "With the forced exercise of warrants possible if AMBS shares trade above $0.10, this transaction will allow the Company to operate well into 2014, where we expect to begin generating revenue through LymPro commercialization and bring MANF closer to first-in-man human clinical studies." said Gerald E. Commissiong, President & CEO of Amarantus.
There is a post on seeking alpha to the following link:
http://www.sciencedaily.com/releases/2013/07/130728221518.htm
It is really good news for Alzheimer's (and therefore, other disease) patients that science is making progress in developing diagnostic tools for distinguishing Alzheimer's patients and patients with other neuro degenerative disorders. A single blood based kit might not be able to cover all age groups or patients at various stages. I hope this kit to successfully clear all hurdles and make it to the doctors.
From AMBS's point of view, it is great news that there is a healthy competition. In science, the more you know, the more you progress. So, any failures/success with the above kit, will only help AMBS (just like GDNF helped AMBS to avoid the pitfalls, so far). Also, think about the kind of publicity a successful LymPro Tool could bring to AMBS. I expect documentaries and in-studio live interviews coming up. LymPro will be a household name. ARNA's Belviq had made it to all news channels and some even had panel discussions on what it meant to the US population.
As per my sources, LymPro CLIA deal was sealed in the last week of August.
Those who do not know AMBS's Helsinki connection: Give it a read, and if possible, read the published paper itself.
http://ir.stockpr.com/amarantus/company-news/detail/173/amarantus-biosciences-announces-landmark-manf-genomics-publication
The MANF-family (MANF and CDNF) of proteins are remarkably conserved in evolution in multicellular organisms. Previous studies in Dr. Heino's laboratory carried out by Palgi et al. demonstrate that fruit fly, Drosophila melanogaster, Manf (DmMANF) is a true orthologue to mammalian MANF, meaning that the proteins have similar biological functions in the two systems.
"Give a man a fish and you feed him for a day. Teach a man to fish and you feed him for a lifetime."
Hopefully, investing in AMBS has been a learning curve for investors with various levels of trading experience. Remember that trading is not just about buying/selling. It is about observing, analyzing different situations, making good/bad choices, and emerging with real-life experiences that no textbook or degree can teach you.
Chapter 1 (Introduction to AMBS) has come to an end. As AMBS embarks on chapter 2 (Mighty Oaks From Little Acorns Grow) of its epic journey, starting next week, I congratulate all investors/scientists/researchers for their efforts.
It is time ...
Eli Lilly is continuing to pursue its stage-three trial of solanezumab since the data indicate that it slowed cognitive decline in early-stage patients by 34 percent. All pharmaceuticals in Alzheimer's research are unanimous that the key to cure Alzheimer's could lie in the early detection of the symptoms. LymPro, a blood based diagnostic assay being developed by Amarantus BioScience Holdings Inc. (ticker AMBS) has shown 98%/96% sensitivity/specificity in detecting and distinguishing Alzheimer's from other forms of dementia, in a study of 160 patient population. LymPro is currently undergoing validation tests at the Becton Dickinson (BD) diagnostic systems. A successful trail could kick-start efforts to cure Alzheimer's in what is potentially a 20 billion dollar market.
AMBS will be releasing data related to its various milestones in the second week of September. Being a scientist, one thing I can tell you what researchers and scientists absolutely love and drool on: POSITIVE DATA. How many of you seriously think that with billions of dollars to tap, no pharmaceutical company is looking at or interested in LymPro? Just wait until AMBS officially releases the BD results (which I can confirm are outrageously good). You will get your answers.
Be proactive, is all I can say.
GIA is an option for sure, just that is not on the horizon by a long long shot. AMBS needs a worldwide distributor for LymPro.
I can now confirm (people can question, but that is not my problem) that LymPro analytical performance in BD lab has returned stupendous numbers. The 96/98 % specificity/sensitivity has been replicated, confirming AMBS's previous study with 160 patient population.The focus has now shifted to who AMBS selects to carry out the CLIA work which should bring some decent funding to AMBS.
By the way, the recent run from 0.03 to 0.09 was not a fluke. Gerald was invited all the way to Helsinki not to just sit on a Alz discussion for 1 hour. Yesterday's little 30% stunt was staged by crooks. It is a shame such things are allowed by SEC. Watch out for some real fun, real soon. It is time to be pleasantly surprised.
Reading most of the posts here, it is clear why 95% investors with less than 5 years of trading experience lose all their hard earned savings. It is true that the stock is down 25% and could end at $0.03 by the end of the day. Yes, you could be losing (only if you sell) almost 65% of your investment if you bought at $0.08. The question you want to answer is: Is AMBS going to remain at ~0.04 levels for long? If you can't trust your own judgement, it is in the best interest of you and your family that you get out of the market.
Regarding AMBS, I am thrilled to know that funding has been secured that will last for the next 18 months (until Feb 2015). Finding institutional investors to fund a startup is like going to the space station. The space station is set up to do science, but every time you have to go there, the trip itself becomes the priority due to the risks involved. Likewise, for a biotech funding often becomes more important than the science itself. It is a tremendous boost of confidence for new investors that AMBS has the financing it needs to file the orphan INDs, LymPro commercialization, MANF clinical trials and proceed with the PhaseIIb trials for the drug for which LOI was obtained.
The Alzheimer's discussion this morning at Helsinki was a great success and it was very informative to hear the technology that the panelists are working on. Looking forward to the realization of my other predictions. People who understand the game, do not fret about the pps being a few cents here or there. Q3 2013 has defined the course of action for AMBS's blockbuster success. Stay tuned. Life is stranger than fiction.
AMBS has secured private funding to fund the further development of its product development programs, MANF and LymPro. Another of my predictions has hit bull's eye. Gerald has indirectly told investors that LemPro results are positive (98%/96% sensitivity/specificity). Stay tuned for MANF-CED deal.
MY POST ON AUG 12:
"According to my research and sources, AMBS will be announcing funding (continuation of the bridge-financing achieved in June 2013) in the next 14-21 days. I hope the news does not come before Aug 29. It will give me a chance to increase my investment by another 25%."
http://www.nj.com/business/index.ssf/2013/05/novartis_looks_to_become_playe.html
"Novartis is pursuing alternatives including licensing agreements. This remains high on our radar, with high unmet medical need. It’s an area that we haven’t given up on."
Since the Exelon patch works for Parkinson's patients as well, AMBS's LymPro/NuroPro diagnostic Kits could have a game-changing role to play for Novartis. From both science and investment point of views, Novartis's efforts to find the underlying causes of Alz and PD could be served well by AMBS's research.
Please remember that the pps is not the important thing right now. What matters is how many shares you have, because each of those will be ~$10 by Dec 2014, as per my calculations.
I am in Heidelberg and just got updated by my sources (that I do not trust myself !!) that Novartis is in the mix. Helsinki could have invited much higher-profiled Alzheimer's player from the US, but they chose the unknown AMBS due to Novartis wanting to know more about their highly sensitive/specific (98%/96%) LymPro Test.
Keep in mind that the fight is on, amongst global pharmaceutical companies, for who can develop the early stage diagnostic tool. As I always say, Science will take care of the pps. The rest, is just details.
A related article from a month ago:
http://www.nj.com/business/index.ssf/2013/07/latest_fda_approval_of_alzheim.html
"Novartis has stepped up its research to identify the underlying causes of Alzheimer’s, just as several pharmaceutical companies have experienced serious setbacks in their efforts. Over the past year, experimental Alzheimer’s drugs from Baxter and two from Ely Lilly — developed by Pfizer, J&J and Elan — have failed in clinical trials. In April, Bridgewater-based Sanofi said it wouldn’t invest in Alzheimer’s research because the available science didn’t justify the heavy financial cost.
But with a potential market of $20 billion by some estimates, substantial investment remains from other pharmaceutical companies and research institutions. Drugmakers like Roche and Genentech, along with Ely Lilly and Whitehouse Station-based Merck, are still trying to develop an effective Alzheimer’s drug"
As I posted a month ago, AMBS is looking beyond the intermediate LymPro tests, at worldwide distribution. All these tests are a mere formality, for book keeping purposes. As I have mentioned a few times lately that "LymPro results will be released in these 7-10 days." Glad that Gerald has indirectly let known that BD tests have come out positive. Stay tuned for the rest of my predictions (to be honest, I cheat a bit as I know a thing or two about AMBS). But hey, why complain if the info is correct and good !! Remember, your job as an investor is to be pro-active, because the market is always reactive and thus late.
Keep in mind that Gerald's Helsinki presentation is going to focus on the science, data and development strategy for the LymPro Test. During the presentation, Gerald may/maynot choose to release the BD LymPro analytical performance results. In my opinion, he will not. And reserve all announcements to be made after the conference. Either way works for me, I will be adding 10% to my position irrespective of whether the pps is 0.04 or 0.12 ...
http://neuroscene.com/?p=111
Some posters questioned why Big Pharma have not scooped up AMBS already? Here is your answer: The audio explains why GDNF for PD failed (inspite of being extremely potent), at 09:25 minutes. And discusses Alzheimer's at 10:30 minutes.
This is where MANF-CED partnership will be a game-changer. We already know that MANF is better than the extremely-potent-GDNF. If successful (my experience says it will be), AMBS will be a page-1 headline on every newspaper, magazine and news channel. I see AMBS MANF PD programme getting a $2B+ funding from Big Pharma, in a year or so. There is a reason why Dr. Rubinfeld decided to be an advisor to a virtually unknown (yet) AMBS.
Forget about "AMBS the company". Concentrate on "AMBS the research organization". And remember that great things come in small packages.
Take a listen as to why it is critical for any Parkinson's drug to effectively cross the Blood Brain Barrier.
http://neuroscene.com/?p=111
98% of the water soluble molecules can't cross the BBB, and end up in lever or kidney. The molecules having not reached the desired areas in the brain, lead to the apparent failure of the drug trial, leading to termination of the research. The problem is not the drug, rather how to deliver it to the desired area in the brain.
Convection-Enhanced Delivery has come to the rescue of many drugs, by successfully delivering the right dosage across the BBB. MANF has shown to stop and reverse Parkinson's disease in rats. AMBS is now going to use CED and deliver MANF to human brains and see how effective MANF is. Given that MANF has not shown any side effects, and has been shown to be better than the gold standard GDNF, there is a very high probability that MANF human trials will be successful.
Clarification:
I am not bullish/bearish/pro/anti any stock/company/analyst/opinion. It does not matter what I think or "believe". I do not sit in my garden and say "Oh, what if this stock doubles!!... Gee, I believe this company is doomed...". Having been a student of science all my life, I only care for repeatable scientific results. It does not matter to me whether AMBS market cap is 20M or 20 Trillion. I only want to know what the company is doing in its labs and is it any good for the patients. And the way I see it (unless AMBS is a scam, which is as likely as an Alien visiting me), the results have come out positive at a statistically significant level. For a scientist, nothing rings the bells more than when the data comes out statistically significant. In AMBS's case, the data has been and is being independently verified. That is all I need to know. The numbers $0.07, $1, $50, 20M, 20B... are just numbers. They will change all the time.
What is important is that the numbers coming out of the AMBS lab don't change! If they do, I would not be here.
A century ago, a group of European physicists showed crazy data at the sub-atomic scales (Quantum physics). Einstein prematurely dismissed the notion that the laws of nature are probabilistic, and famously said that he "believes" that "God does not play dice". He was later proved to be wrong.
Bottom line, it does not matter what anyone "believes" in. Scientific results is all that matters, no matter howsoever crazy. Stay tuned. AMBS will surprise many.
Please take a listen (4:00 - 5:40).
http://ir.stockpr.com/amarantus/videos/view/104/amarantus-at-onemedforumny-2013
Important points:
1. BD was selected by AMBS so that standard operating procedures and methods could be followed, while developing the LymPro assay for worldwide distribution. The invitation to the Helsinki Summit is not an isolated incident.
2. CED specailist for MANF has been selected (to be announced soon).
3. Early Orphan data (MCI, Diabetes, TBI) has been encouraging. The recent Type1-Diabetes grant to Saarma et al. at the University of Helsinki to study MANF is not an isolated incident.
AMBS is keeping a lot of information collected during the 2nd and 3rd quarters, from the public eye. Most investors and analysts have little idea as to what the company has managed to achieve over the past 60 days. The $0.25 target is old news. The orphan indications when accounted for, will lead to a pps target of ~$5, which will go higher (~$50) with more data over the next few months. A lot of water has gone down the bridge over the last 2 quarters. This confirms my "chill play" theory. Gerald is going to release the information as and when he feels it is appropriate, keeping an eye on the pps as well. The day-to-day fight over the pps action is irrelevant. When AMBS releases the many details, AMBS pps will soar to $0.75 at least.
AMBS should be announcing funding news any day now. MANF-CED partner to be announced in the next 21 days. My guess is German based BrainLab.
AMBS pps is set to break the yearly high. As per my sources, LymPro analytical study has returned positive data by BD. By the way, MANF orphan indication for ear is positive as well. Price should hit 50 cents in the coming weeks. Stay tuned.
There are a lot of terms (like Breast Cancer, CML, NuroPro CLIA) on this webpage that I do not remember Gerald talking about anymore.
http://ir.stockpr.com/amarantus/company-news/detail/473/amarantus-bioscience-acquires-neurodegenerative-diagnostic-intellectual-property-portfolio-from-power3-medical-products
I understand that LymPro has been the focus off late, but BC SeraPro was all set to hit the clinics in 2009. What happened? And why did Power3 go bankrupt? I am going to raise these questions the next time I talk to Gerald, hopefully later this week.
It has been my view that short selling must be made illegal and brokerage firms must not allow shares to be shorted. Short selling has some merits for banks and companies when they are going through tough times. But to let every tom/dick/harry out there to short stocks is like letting narcotic drugs to be sold over-the-counter. Shorting makes stock markets look like casinos.
I have received a couple of PMs questioning how realistic is it to compare ACAD with AMBS.
Keep in mind that nobody is comparing ACAD and AMBS verbatim. The markets for the two companies are somewhat distinct with markedly different potential. The idea is to provide instances where promising science and technology has been duly appreciated by the market. None of ACAD's products have commercialized yet. All are at various (phase-1,2,3) stages of development. Even if 1 (or more) of its products were to fail clinical trials, ACAD will be able to maintain decent shareholder value. Compare that to 1-drug wonders like PPHM or CLSN. Both dropped around 90% on poor data.
AMBS has shown over the past 10 months what it takes to become a successful biotech. MANF especially has therapeutic use for at least half a dozen indications. At 7 cents, there is no other biotech with such potential (for shareholders and medicine). The orphan data for ear indication is ready and has come out positive, as with the eye a couple of weeks ago. INDs will be submitted soon to FDA. Glad that all 3 of my predictions (chill lift date, post chill target, chill play) have come true.
Stay tuned for (1) funding news, (2) BD validating LymPro analytical data over the next 10 days. (3) Partner for Convection-Enhanced Delivery of MANF has been finalized and will be announced over the next 21 days. Data for MANF delivered via gene-therapy (like Ceregene) will be announced over the next few months.
Something to look forward to: AMBS owns BC SeraPro Blood Test and is ready to hit the US market.
A year ago, on 03 Aug 2012, ACAD closed at $1.5. Now, it is trading around $22. The Company has four product candidates in clinical development led by pimavanserin, which is in Phase III development as a first-in-class treatment for Parkinson's disease psychosis. It holds worldwide commercialization rights to pimavanserin. In addition, the Company has a product candidate in Phase II development for chronic pains and a product candidate in Phase I development for glaucoma, both in collaboration with Allergan, Inc.
With at least a dozen upcoming Orphan Indications, LymPro, NuroPro, MANF patents in Europe and the US, I see AMBS entering multiple collaborations with the leading pharmaceutical companies in the world over the next 12 months. LymPro validation (to be announced next week) and CLIA collaboration will take AMBS to $0.5-1.00. I expect AMBS to be trading atleast at $10 (150X current pps) by Dec 2014.
In a recently completed pre-clinical model of Parkinson's disease funded by MJFF, MANF corrected the neurological deficits when it was given immediately after the animals became sick. MANF also corrected the neurological deficits when it was given three weeks after the models became sick. This means that MANF is able to prevent the death of healthy dopaminergic neurons, but also MANF can save dopaminergic neurons that are already dying.
How do these results apply to human patients? The results suggest that in patients newly diagnosed with Parkinson's disease MANF might be able to save those dopaminergic neurons that are sick and dying, but not yet dead. These patients will likely get better sooner, and their recovery will also last for a longer time. It is much too soon to predict whether MANF will be able to cure Parkinson's disease. MANF is certainly one of the most promising molecules currently in development to treat this debilitating disease.
More than a possibility, if we see what happened to ACAD. Things have changed over the past 25 odd years, since Amgen was launched. The markets have grown, better and faster connected to world markets. The FDA policies have gone a sea change. There is a lot of emphasis on early detection and treatment of symptoms. Orphan status is a lip smacking incentive for any biotech, especially startups. If LymPro, NuroPro and MANF continue to show promise and repeatable results, $50-100 pps is not a far fetched fantasy. It could happen in a year's time. At the OneMed Conf in Jan 2012, I could see the excitement in Dr. Rubinfeld's brief 3 minute talk, when he said we want to take MANF to the market asap. Many of the posters/investors here have no idea what AMBS is doing. They are here just for a quick 10% profit. It will benefit them to google and listen to all AMBS presentations since Jan 2012.
Actually, Let us forget about $50+. Let us suppose the pps is $1 and gains 5 cents, to become $1.05. That is a 5 percent gain. If you buy now when the pps is 5 cents, every 5 cent increment is 100% gain. I honestly do not see any real risk in investing in AMBS. If the pps sinks, just buy more. That is what we have been doing since January 2013. I have bought at 0.17, 0.16, 0.09, 0.06, 0.05, 0.04, 0.03, with an average of 0.05. If EVERYTHING that AMBS has fails, we all know that LymPro alone will still take AMBS to $0.50-1.00. In any case, those who think that AMBS is a risk, well, everything in the stock market is a risk, isn't it?
I ask, tell us one stock that does not have any risk? Believe it or not, AMBS is not the worst answer.
Gerald's reply to me 2 days ago:
"The bottom line is that no one will develop any product involving MANF commercially because we would be in a position to sue and get access to their full revenue stream. SO, anything that is published on MANF really ends up mostly belonging to the Company. Obviously, we would be much more interested in working with these researchers than suing them, so every new publication really validates our patent position and makes our patents more valuable to companies that would be interested in treating any of the diseases MANF appears to be indicated for."
http://www.rndsystems.com/Products/af3748/RelatedInformation
Mature human MANF is 99%, 98% and 96% aa identical to mature rat, mouse and bovine MANF, respectively.
More and more independent research groups across the world have demonstrated the potential of MANF for various indications. In the following work, Hellman et al. show that MANF protects neurons and repairs the Parkinson disease-like symptoms.
http://www.jbc.org/content/286/4/2675.full
Note that MANF not only protects, but repairs as well. For AMBS, the Helsinki Summit is not just about LymPro. I have some investment experience and I have not seen a startup biotech working on so many indications. The 10+ odd potential orphan indications is just magnificent. Usually, startups have 1-2 drugs in their pipelines and if the drugs fail, they sink. AMBS not only works on multiple indications, they seem to have found the solution for these indications, at least with LymPro. This stuff is usually expected from the heavyweights of the biotech world. Make no mistake, AMBS is pulling the right strings and connections. It would not surprise me one bit if the pps crosses $1 by March 2014.
MANF-based cancer therapy is conceivable
"since MANF overexpression decreases proliferation of cultured cancer cells, and decreases cardiomyocyte hypertrophy, a MANF-based cancer therapy is conceivable." -- Christopher C. Glembotski, The SDSU Heart Institute and the Department of Biology, San Diego State University, San Diego, CA 92182, USA
Mission Helsinki
Finally, the pps has started simmering at my post-chill-target of $0.08. Good to have got that done and dusted.
It is time, for AMBS and investors alike, to get serious, put the intelligent heads together, and get some scientific work done. In the midst of all the razzmatazz, no one must ever forget that ultimately AMBS is all about discovering cures to dozens of diseases that I am sure a lot of us can directly/indirectly relate to, through friends and family.
AMBS is now on the cusp of graduating to the real world, of challenges and opportunities. May AMBS bring its A++ game to the park, starting with Sept 4.
It is time to move on, on this great journey that has come to be known as AMBS. This is just the beginning.
As I said 2 weeks ago that "funding news will come in 2-3 weeks time." 2 weeks have passed, which means "watch out for funding news in the next 7-10 days". AMBS will release the BD-LymPro validation results after Helsinki Summit. By the way, I had said that after chill lift, the pps would jump to 0.075-0.08 levels minimum. Getting close to it. Also, as per my sources, CED partner has been identified and AMBS will update market in the next 3 weeks. Do not get too excited by the fact that AMBS is up by a cent. This is just the beginning. AMBS is worth $0.5-1 on LymPro alone. MANF will take AMBS to $50-100. Q3 2013 will define AMBS.
Those who are on the sidelines need to ask themselves: If AMBS is a scam, then it would mean that all independent research groups validating MANF for various indications are scams as well, the peer-reviewed journals are scams, NeuroInsights (the world's leading neurotech market authority) is a scam, BDX and the swiss lab that upheld AMBS findings are scams as well.
While novices fret on the minute-to-minute fluctuations in the hundredth of a cent, investors who understand the game have set their eyes and ears on the upcoming formal presentation to be made by President & CEO Gerald E. Commissiong at the 2nd Annual European Investing and Partnering Summit to be held September 4-5 in Helsinki, Finland, which is being hosted by NeuroInsights. The presentation will focus on the science, data and development strategy for the LymPro Test for Alzheimer's disease.
BD-LymPro CLIA license will be announced post the Helsinki Summit. Stay tuned.
For those who might be wondering WHY MANF PATENTS ARE CRITICAL TO AMBS?
During an email conversation with Jason Napodano, he told me the following:
"If AMBS owns the patents to MANF or the specific indication, then the outside groups can't do anything without AMBS' permission. Most of the time the outside groups are universities or other academic centers. They are not interested in selling the drug, only doing science to publish in peer-reviewed journals. 99 times out of 100 they are working with the company directly."